On May 14, pharmaceutical company Galderma (UK) Limited celebrated 10 years since Azzalure®(AbobotulinumtoxinA) was first approved in Europe for the treatment of glabellar lines.
According to the company, Azzalure®(AbobotulinumtoxinA) is approved in 72 countries worldwide and has been used for more than 40 million glabellar line treatments in Europe and the US alone. As well as this, Azzalure®(AbobotulinumtoxinA) has a well-established safety profile and is supported by 24 studies in aesthetic indications in which more than 6,200 patients were enrolled, Galderma claims.
“We are delighted to reach this 10-year landmark and are looking forward to another decade of high patient and physician satisfaction.” said Patricia Ramos, brand manager, medical solutions, aesthetic and corrective and prescription divisions, Galderma UK and Ireland. She added, “Azzalure®(AbobotulinumtoxinA) is a toxin you can trust, it is made in the UK and has been used for more than 25 years in a clinical environment.”
Full prescribing information for Azzalure® (AbobotulinumtoxinA) can be found here.
